Loading...
Biologics Focus And Divestiture Of Noncore Assets Will Drive Long Term Earnings Power
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
1Y
114.2%7D
6.4%1Y
114.2%7D
6.4%You can edit this narrative until Dec 19 12:11 AM. Then, changes will post as Updates.